文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

克拉霉素用于希腊社区获得性肺炎早期抗炎反应(ACCESS):一项随机双盲安慰剂对照试验

Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2024-01-03
一句话结论住院社区获得性肺炎患者在β-内酰胺基础上加用克拉霉素500 mg每日两次口服7天,第4天早期临床应答复合终点达成率68% vs 38%,作者认为应加用以实现早期临床应答和炎症负荷下降。

ACCESS为3期前瞻性双盲随机安慰剂对照试验,纳入希腊18个内科病房住院的成人社区获得性肺炎患者,要求存在全身炎症反应综合征、SOFA评分≥2分且降钙素原≥0.25 ng/mL;按1:1随机接受标准治疗(含静脉第三代头孢菌素或静脉β-内酰胺加β-内酰胺酶抑制剂)联合口服克拉霉素500 mg每日两次共7天或口服安慰剂。主要复合终点要求72小时后(治疗第4天)同时满足呼吸道症状严重度评分下降≥50%和SOFA评分下降至少30%或降钙素原有利动力学(较基线下降≥80%或降钙素原<0.25 ng/mL)之一。克拉霉素组91例(68%)、安慰剂组51例(38%)达到主要终点(差值29.6%[95%CI 17.7-40.3];OR 3.40[95%CI 2.06-5.63];p<0.0001)。严重治疗中出现不良事件克拉霉素组58例(43%)、安慰剂组70例(53%)(差值9.4%[95%CI -2.6至20.9];OR 0.67[95%CI 0.42至1.11];p=0.14),无一例严重不良事件判定与分组相关。

要点

  • 住院社区获得性肺炎合并SIRS、SOFA≥2分、降钙素原≥0.25 ng/mL者,加用克拉霉素500 mg每日两次口服7天,第4天主要复合终点达成率68% vs 38%(OR 3.40,95%CI 2.06-5.63;p<0.0001)。
  • 主要终点要求同时满足呼吸道症状严重度评分下降≥50%与SOFA评分下降至少30%或降钙素原有利动力学(较基线下降≥80%或<0.25 ng/mL)之一。
  • 严重治疗中出现不良事件克拉霉素组43% vs 安慰剂组53%(OR 0.67,95%CI 0.42-1.11;p=0.14),差异未达统计学显著,无一例判定与分组相关。
  • 作者认为,这些发现提示在β-内酰胺基础上加用克拉霉素对住院社区获得性肺炎患者实现早期临床应答和早期炎症负荷下降具有重要意义。

适用人群与场景

  • 希腊18个公立医院内科病房住院的成人社区获得性肺炎患者,需存在全身炎症反应综合征、SOFA评分≥2分且降钙素原≥0.25 ng/mL。

诊断标准与关键阈值

  • 纳入标准:住院成人社区获得性肺炎,存在全身炎症反应综合征、SOFA评分≥2分、降钙素原≥0.25 ng/mL。
  • 主要复合终点(治疗第4天,即72小时后)需同时满足:(1)呼吸道症状严重度评分下降≥50%(早期临床应答指标);(2)SOFA评分下降至少30%或降钙素原有利动力学(定义为较基线下降≥80%或降钙素原<0.25 ng/mL),或两者兼有(早期炎症反应指标)。

处置流程与药物剂量

  • 标准治疗药物包括静脉第三代头孢菌素或静脉β-内酰胺加β-内酰胺酶抑制剂组合。
  • 在标准治疗基础上加用口服克拉霉素500 mg每日两次,疗程7天;对照为口服安慰剂。

研究设计与关键结果

  • ACCESS为3期前瞻性、双盲、随机对照试验,在希腊18个内科病房开展;2021年1月25日至2023年4月11日纳入278例,按1:1随机分配至克拉霉素组(n=139)或安慰剂组(n=139)。
  • 主要终点分析纳入克拉霉素组134例(5例撤回知情同意)和安慰剂组133例(6例撤回知情同意)。
  • 主要复合终点达成:克拉霉素组91例(68%)vs 安慰剂组51例(38%),差值29.6%(95%CI 17.7-40.3),OR 3.40(95%CI 2.06-5.63),p<0.0001。
  • 严重治疗中出现不良事件:克拉霉素组58例(43%)vs 安慰剂组70例(53%),差值9.4%(95%CI -2.6至20.9),OR 0.67(95%CI 0.42至1.11),p=0.14;无一例严重不良事件判定与分组相关。

证据类型、等级与局限

  • 证据类型:3期前瞻性、双盲、随机安慰剂对照试验(ACCESS)。
  • 试验注册于EU Clinical Trials Register(2020-004452-15)和ClinicalTrials.gov(NCT04724044)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现提示在β-内酰胺基础上加用克拉霉素对住院社区获得性肺炎患者实现早期临床应答和早期炎症负荷下降具有重要意义;机制获益与免疫应答改变相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of patients in hospital with community-acquired pneumonia is based on results from observational studies and meta-analyses rather than randomised clinical trials. We investigated if addition of the macrolide clarithromycin to treatment with a β-lactam antibiotic in this population could improve early clinical response-the new regulatory endpoint for community-acquired pneumonia-and explored the possible contribution of modulation of the inflammatory host response to that outcome.

METHODS: The ACCESS trial was a phase 3 prospective, double-blind, randomised controlled trial, in which adults in hospital with community-acquired pneumonia who had systemic inflammatory response syndrome, Sequential Organ Failure Assessment (SOFA) score of 2 or more, and procalcitonin 0·25 ng/mL or more were enrolled in 18 internal medicine departments of public Greek hospitals. Patients were randomly assigned (1:1) by computer-generated block randomisation to standard of care medication (including intravenous administration of a third-generation cephalosporin or intravenous administration of β-lactam plus β-lactamase inhibitor combination) plus either oral placebo or oral clarithromycin 500 mg twice daily for 7 days. Investigators, staff, and patients were masked to group allocation. The primary composite endpoint required that patients fulfilled both of the following conditions after 72 hours (ie, day 4 of treatment): (1) decrease in respiratory symptom severity score of 50% or more as an indicator of early clinical response and (2) decrease in SOFA score of at least 30% or favourable procalcitonin kinetics (defined as ≥80% decrease from baseline or procalcitonin <0·25 ng/mL), or both, as an indicator of early inflammatory response. Participants who were randomly assigned and received allocated treatment were included in the primary analysis population. This trial is complete and is registered with the EU Clinical Trials Register (2020-004452-15) and ClinicalTrials.gov (NCT04724044).

FINDINGS: Patients were enrolled between Jan 25, 2021, and April 11, 2023, and 278 individuals were randomly allocated to receive standard of care in combination with either clarithromycin (n=139) or placebo (n=139). 134 patients in the clarithromycin group (five withdrew consent) and 133 patients in the placebo group (six withdrew consent) were included in the analysis of the primary endpoint. The primary endpoint was met in 91 (68%) patients in the clarithromycin group and 51 (38%) patients in the placebo group (difference 29·6% [95% CI 17·7-40·3]; odds ratio [OR] 3·40 [95% CI 2·06-5·63]; p<0·0001). Serious treatment-emergent adverse events (TEAEs) occurred in 58 (43%) patients in the clarithromycin group and 70 (53%) patients in the placebo group (difference 9·4% [95% CI -2·6 to 20·9]; OR 0·67 [95% CI 0·42 to 1·11]; p=0·14). None of the serious TEAEs was judged to be related to treatment assignment.

INTERPRETATION: Addition of clarithromycin to standard of care enhances early clinical response and attenuates the inflammatory burden of community-acquired pneumonia. The mechanism of benefit is associated with changes in the immune response. These findings suggest the importance of adding clarithromycin to β-lactams for treatment of patients in hospital with community-acquired pneumonia to achieve early clinical response and early decrease of the inflammatory burden.

FUNDING: Hellenic Institute for the Study of Sepsis and Abbott Products Operations.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2024. PMID: 38184008. doi:10.1016/S2213-2600(23)00412-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。